| 1 | Oral squamous cell carcinomas:state of the field and emerging directions显示文摘Oral squamous cell carcinoma (OSCC) develops on the mucosal epithelium of the oral cavity. It accounts for approximately 90% oforal malignancies and impairs appearance, pronunciation, swallowing, and flavor perception. In 2020, 377,713 OSCC cases werereported globally. According to the Global Cancer Observatory (GCO), the incidence of OSCC will rise by approximately 40% by2040, accompanied by a growth in mortality. Persistent exposure to various risk factors, including tobacco, alcohol, betel quid (BQ),and human papillomavirus (HPV), will lead to the development of oral potentially malignant disorders (OPMDs), which are oralmucosal lesions with an increased risk of developing into OSCC. Complex and multifactorial, the oncogenesis process involvesgenetic alteration, epigenetic modification, and a dysregulated tumor microenvironment. Although various therapeuticinterventions, such as chemotherapy, radiation, immunotherapy, and nanomedicine, have been proposed to prevent or treat OSCCand OPMDs, understanding the mechanism of malignancies will facilitate the identification of therapeutic and prognostic factors,thereby improving the efficacy of treatment for OSCC patients. This review summarizes the mechanisms involved in OSCC.Moreover, the current therapeutic interventions and prognostic methods for OSCC and OPMDs are discussed to facilitatecomprehension and provide several prospective outlooks for the fields. | Yunhan Tan Zhihan Wang Mengtong Xu Bowen Li Zhao Huang Siyuan Qin Edouard C.Nice Jing Tang Canhua Huang | 2023 | International Journal of Oral Science2023，15，4： | 0 |
| 2 | Luteolin suppresses oral carcinoma 3(OC3) cell growth and migration via modulating polo-like kinase 1(PLK1) expression and cellular energy metabolism显示文摘Oral squamous cell carcinoma(OSCC)is a prevalent malignant tumor affecting the head and neck region(Leemans et al.,2018).It is often diagnosed at a later stage,leading to a poor prognosis(Muzaffar et al.,2021;Li et al.,2023).Despite advances in OSCC treatment,the overall 5-year survival rate of OSCC patients remains alarmingly low,falling below 50%(Jehn et al.,2019;Johnson et al.,2020).According to statistics,only 50%of patients with oral cancer can be treated with surgery.Once discovered,it is more frequently at an advanced stage.In addition,owing to the aggressively invasive and metastatic characteristics of OSCC,most patients die within one year of diagnosis.Hence,the pursuit of novel therapeutic drugs and treatments to improve the response of oral cancer to medication,along with a deeper understanding of their effects. | Pengfei GAO Wentao ZHANG Yujie LIN Ruijie LU Zijian LOU Gang LU Ruolang PAN Yunfang CHEN | 2023 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2023，24，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员